SPI 3608

Drug Profile

SPI 3608

Alternative Names: SPI-3608

Latest Information Update: 30 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sucampo Pharmaceuticals
  • Class Fatty acids
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Spinal stenosis

Most Recent Events

  • 30 Mar 2016 Discontinued - Phase-I for Spinal stenosis (In volunteers) in Japan (PO)
  • 05 Aug 2014 Sucampo completes phase Ib trial (in healthy volunteers) in Spinal stenosis
  • 23 May 2014 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top